.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Argus Health
Fish and Richardson
Dow
Novartis
Accenture
Colorcon
Johnson and Johnson
Teva

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,063,811

« Back to Dashboard

Which drugs does patent 6,063,811 protect, and when does it expire?


Patent 6,063,811 protects VIOXX and is included in two NDAs.

Protection for VIOXX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in thirty-one countries.

Summary for Patent: 6,063,811

Title: Compositions for a once day treatment of cyclooxygenase-2 mediated diseases
Abstract:This application relates to a method of treating a disease susceptible to treatment with a non-steroidal anti-inflammatory drug by administering to a patient once daily an effective amount of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone.
Inventor(s): Hancock; Bruno (Beaconsfield, CA), Winters; Conrad (L'Ile Bizard, CA), Gertz; Barry (Summit, NJ), Ehrich; Elliot (Chatham, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ) Merch Frosst Canada & Co. (Kirkland, CA)
Application Number:09/180,647
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-001May 20, 1999DISCNNoNo► Subscribe► SubscribeY
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-002May 20, 1999DISCNNoNo► Subscribe► SubscribeY
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-003Feb 25, 2000DISCNNoNo► Subscribe► SubscribeY
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-001May 20, 1999DISCNNoNo► Subscribe► SubscribeY
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-002May 20, 1999DISCNNoNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,063,811

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9612063Jun 10, 1996
PCT Information
PCT FiledMay 13, 1997PCT Application Number:PCT/US97/08041
PCT Publication Date:November 27, 1997PCT Publication Number: WO97/44028

International Patent Family for Patent: 6,063,811

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway985342► Subscribe
New Zealand332670► Subscribe
South Korea20000011082► Subscribe
South Korea100373622► Subscribe
Iceland4891► Subscribe
JapanH11512754► Subscribe
Israel126899► Subscribe
Indonesia16921► Subscribe
Hungary9902889► Subscribe
CroatiaP970262► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Healthtrust
Chinese Patent Office
Fish and Richardson
Chubb
McKinsey
Mallinckrodt
US Department of Justice
Harvard Business School
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot